Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control data.
Saved in:
| Title: | Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control data. |
|---|---|
| Authors: | Schelter BO; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Institute for Complex Systems and Mathematical Biology, University of Aberdeen, Aberdeen, UK., Shiells H; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK., Lo S; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Institute for Complex Systems and Mathematical Biology, University of Aberdeen, Aberdeen, UK., Nazlee N; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK., Evans E; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK., Bentham P; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, UK., Gauthier S; Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada., Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom; UK Dementia Research Institute at UCL, London, United Kingdom; Hong Kong Centre for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China; Wisconsin Alzheimer's Disease Research Centre, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison WI 53792, USA., Wilcock GK; Geratology, University of Oxford, Oxford, UK., Froelich L; Department of Geriatric Psychiatry, Medical Faculty Mannheim, Central Institute of Mental Health, Heidelberg University, Mannheim (SCU-B), Germany., Burns A; University of Manchester, Manchester, UK., MacSweeney E; Re:Cognition Health London UK., Ballard C; Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK., Yu JT; Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China., Choon TS; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK., Asvatourian V; Cytel Inc. 675 Massachusetts Ave, Cambridge, MA 02139, USA., Muehlemann N; Cytel Inc. 675 Massachusetts Ave, Cambridge, MA 02139, USA., Priel J; Cytel Inc. 675 Massachusetts Ave, Cambridge, MA 02139, USA., Kook K; Salamandra LLC, Bethesda, MD, USA., Sullivan T; Salamandra LLC, Bethesda, MD, USA., Downie D; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK., Miller S; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK., Pringle C; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK., Storey JMD; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, UK., Baddeley T; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, UK., Harrington CR; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK., Staff R; Aberdeen Royal Infirmary NHS Grampian, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, UK., Sandu AL; Aberdeen Biomedical Imaging Centre, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Lilian Sutton Building, Foresterhill, Aberdeen AB25 2ZD, UK., Hull C; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK., Stefanacci R; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Thomas Jefferson University, Philadelphia, PA, USA., Wischik CM; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK. Electronic address: cmw@taurx.com. |
| Corporate Authors: | Alzheimer's Disease Neuroimaging Initiative |
| Source: | The journal of prevention of Alzheimer's disease [J Prev Alzheimers Dis] 2026 Jun; Vol. 13 (6), pp. 100560. Date of Electronic Publication: 2026 Apr 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer International Publishing Country of Publication: United States NLM ID: 101638820 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2426-0266 (Electronic) Linking ISSN: 22745807 NLM ISO Abbreviation: J Prev Alzheimers Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42000569 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control data. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Schelter+BO%22">Schelter BO</searchLink>; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Institute for Complex Systems and Mathematical Biology, University of Aberdeen, Aberdeen, UK.<br /><searchLink fieldCode="AU" term="%22Shiells+H%22">Shiells H</searchLink>; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK.<br /><searchLink fieldCode="AU" term="%22Lo+S%22">Lo S</searchLink>; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Institute for Complex Systems and Mathematical Biology, University of Aberdeen, Aberdeen, UK.<br /><searchLink fieldCode="AU" term="%22Nazlee+N%22">Nazlee N</searchLink>; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK.<br /><searchLink fieldCode="AU" term="%22Evans+E%22">Evans E</searchLink>; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK.<br /><searchLink fieldCode="AU" term="%22Bentham+P%22">Bentham P</searchLink>; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, UK.<br /><searchLink fieldCode="AU" term="%22Gauthier+S%22">Gauthier S</searchLink>; Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.<br /><searchLink fieldCode="AU" term="%22Zetterberg+H%22">Zetterberg H</searchLink>; Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom; UK Dementia Research Institute at UCL, London, United Kingdom; Hong Kong Centre for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China; Wisconsin Alzheimer's Disease Research Centre, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison WI 53792, USA.<br /><searchLink fieldCode="AU" term="%22Wilcock+GK%22">Wilcock GK</searchLink>; Geratology, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Froelich+L%22">Froelich L</searchLink>; Department of Geriatric Psychiatry, Medical Faculty Mannheim, Central Institute of Mental Health, Heidelberg University, Mannheim (SCU-B), Germany.<br /><searchLink fieldCode="AU" term="%22Burns+A%22">Burns A</searchLink>; University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22MacSweeney+E%22">MacSweeney E</searchLink>; Re:Cognition Health London UK.<br /><searchLink fieldCode="AU" term="%22Ballard+C%22">Ballard C</searchLink>; Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.<br /><searchLink fieldCode="AU" term="%22Yu+JT%22">Yu JT</searchLink>; Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Choon+TS%22">Choon TS</searchLink>; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK.<br /><searchLink fieldCode="AU" term="%22Asvatourian+V%22">Asvatourian V</searchLink>; Cytel Inc. 675 Massachusetts Ave, Cambridge, MA 02139, USA.<br /><searchLink fieldCode="AU" term="%22Muehlemann+N%22">Muehlemann N</searchLink>; Cytel Inc. 675 Massachusetts Ave, Cambridge, MA 02139, USA.<br /><searchLink fieldCode="AU" term="%22Priel+J%22">Priel J</searchLink>; Cytel Inc. 675 Massachusetts Ave, Cambridge, MA 02139, USA.<br /><searchLink fieldCode="AU" term="%22Kook+K%22">Kook K</searchLink>; Salamandra LLC, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Sullivan+T%22">Sullivan T</searchLink>; Salamandra LLC, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Downie+D%22">Downie D</searchLink>; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK.<br /><searchLink fieldCode="AU" term="%22Miller+S%22">Miller S</searchLink>; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK.<br /><searchLink fieldCode="AU" term="%22Pringle+C%22">Pringle C</searchLink>; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK.<br /><searchLink fieldCode="AU" term="%22Storey+JMD%22">Storey JMD</searchLink>; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, UK.<br /><searchLink fieldCode="AU" term="%22Baddeley+T%22">Baddeley T</searchLink>; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, UK.<br /><searchLink fieldCode="AU" term="%22Harrington+CR%22">Harrington CR</searchLink>; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK.<br /><searchLink fieldCode="AU" term="%22Staff+R%22">Staff R</searchLink>; Aberdeen Royal Infirmary NHS Grampian, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, UK.<br /><searchLink fieldCode="AU" term="%22Sandu+AL%22">Sandu AL</searchLink>; Aberdeen Biomedical Imaging Centre, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Lilian Sutton Building, Foresterhill, Aberdeen AB25 2ZD, UK.<br /><searchLink fieldCode="AU" term="%22Hull+C%22">Hull C</searchLink>; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK.<br /><searchLink fieldCode="AU" term="%22Stefanacci+R%22">Stefanacci R</searchLink>; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Thomas Jefferson University, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Wischik+CM%22">Wischik CM</searchLink>; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK. Electronic address: cmw@taurx.com. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22Alzheimer's+Disease+Neuroimaging+Initiative%22">Alzheimer's Disease Neuroimaging Initiative</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101638820%22">The journal of prevention of Alzheimer's disease</searchLink> [J Prev Alzheimers Dis] 2026 Jun; Vol. 13 (6), pp. 100560. <i>Date of Electronic Publication: </i>2026 Apr 17. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+International+Publishing%22">Springer International Publishing </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101638820 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2426-0266 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2222745807%22">22745807 </searchLink><i>NLM ISO Abbreviation: </i>J Prev Alzheimers Dis <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42000569 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.tjpad.2026.100560 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 100560 Titles: – TitleFull: Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control data. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Schelter BO – PersonEntity: Name: NameFull: Shiells H – PersonEntity: Name: NameFull: Lo S – PersonEntity: Name: NameFull: Nazlee N – PersonEntity: Name: NameFull: Evans E – PersonEntity: Name: NameFull: Bentham P – PersonEntity: Name: NameFull: Gauthier S – PersonEntity: Name: NameFull: Zetterberg H – PersonEntity: Name: NameFull: Wilcock GK – PersonEntity: Name: NameFull: Froelich L – PersonEntity: Name: NameFull: Burns A – PersonEntity: Name: NameFull: MacSweeney E – PersonEntity: Name: NameFull: Ballard C – PersonEntity: Name: NameFull: Yu JT – PersonEntity: Name: NameFull: Choon TS – PersonEntity: Name: NameFull: Asvatourian V – PersonEntity: Name: NameFull: Muehlemann N – PersonEntity: Name: NameFull: Priel J – PersonEntity: Name: NameFull: Kook K – PersonEntity: Name: NameFull: Sullivan T – PersonEntity: Name: NameFull: Downie D – PersonEntity: Name: NameFull: Miller S – PersonEntity: Name: NameFull: Pringle C – PersonEntity: Name: NameFull: Storey JMD – PersonEntity: Name: NameFull: Baddeley T – PersonEntity: Name: NameFull: Harrington CR – PersonEntity: Name: NameFull: Staff R – PersonEntity: Name: NameFull: Sandu AL – PersonEntity: Name: NameFull: Hull C – PersonEntity: Name: NameFull: Stefanacci R – PersonEntity: Name: NameFull: Wischik CM IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2026 Jun Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 2426-0266 Numbering: – Type: volume Value: 13 – Type: issue Value: 6 Titles: – TitleFull: The journal of prevention of Alzheimer's disease Type: main |
| ResultId | 1 |
